mariax / Shutterstock.com
Alphabet-owned GV (formerly Google Ventures) has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Google, Alphabet, Google Ventures, Verve Therapeutics, coronary artery disease, CRISPR, gene editing, genetics, cardiovascular